Agence Nationale De Valorisation De La Recherche (anvar)

Rhone-poulenc Sante

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Institut Des Vaisseaux Et Du Sang

Institut Des Vaisseaux Et Du Sang (ivs)

Rhone Poulenc Sante, French Body Corporate

Pierre Jolles

Daniele Migliore-Samour

Fabienne Parker

Ludovic O Drouet

Jean Lunel

Denise Mancy

Jean Florent

Claudine Soria

Monika Casaretto

Elisabeth Mazoyer

Sylviane Levy Toledano

Anne-Marie Fiat

Sanghamitra Raha

Ann-Taiic D Fiat

Elisobeth M Mazoyer

Levy-Toledano Sylviane

Claire Bal Dit Sollier

The invention relates to the use of .kappa.-caseinoglycopeptide or CGP, in particular from cow's ewe's, goat's or human milk, for the manufacture of a composition, in particular a medicament, for the prevention and/or the treatment of thrombi. A medicament of this kind can advantageously be presented in lyophilised form intended for injection, after being dissolved in a compatible solvent, or in the form of nanoparticles enclosed in capsules. Application to the prevention and the treatment of thrombi.

Method of preventing or treating thrombosis using

The peptides according to the invention are of the following general formula I:

Tetra- and pentapeptides containing the lysyl-arginyl-aspartyl sequence

New immunostimulant substances are obtained by hydrolysing delipidized bovine casein with a proteolytic enzyme and fractionating the product.

Biologically active substances and compositions containing the same

Immuno stimulant substances derived from bovine casein and compositions

Tripeptides composed of the amino acids glycine, leucine, and phenylalanine or tyrosine obtainable by fractionation of hydrolysis products of human casein or by direct synthesis can be used as immunostimulants.

Tripeptides and their use

New immunostimulant substances are obtained by hydrolyzing reduced and alkylated bovine fibrinogen with a proteolytic enzyme and fractionating the product.

Biologically active substances from fibrinogen their preparation and

Hexapeptide, process for obtaining II and the pharmaceutical

Biologically active substances, their obtainment from human casein and

The invention relates to novel water-soluble compounds, process for their preparation, methods of therapeutic treatment therewith and pharmaceutical compositions containing them. The compounds correspond to the formulae (III) and (IV) below or their mixtures in molar proportions of about 4/1, in which formulae X represents a RCO radical and Y represents a hydrogen atom or a RCO radical, or again in which Y represents a RCO radical and X represents a hydrogen atom or a RCO radical, R being an alkyl or alkenyl radical containing 11 to 19 carbon atoms in a straight or branched chain. ##STR1## The compounds are useful as immunological adjuvants.

Novel water-soluble compounds derived from extracts of streptomyces

Novel derivatives with immunological activity are obtained by reacting a hydrosoluble extract of mycobacteria with an aliphatic acid derivative containing 10 to 18 carbon atoms and isolating the resulting product. The hydrosoluble extract of mycobacteria is a tetrasaccharide-heptapeptide or its dimer, trimer or tetramer possibly associated with non-amino reducing sugars. The derivative has the formula: ##STR1## IN WHICH M IS A WHOLE NUMBER COMPRISED BETWEEN 1 AND 4 INCLUSIVE, N IS A WHOLE NUMBER AT LEAST EQUAL TO 1 AND R is an alkyl radical containing 9 to 17 carbon atoms.

Novel immunological adjuvants, process for their production and

There is disclosed a process for obtaining acetylated watersoluble extracts of corynebacteria and specifically of Corynebacterium parvum, of low molecular weight. Said process comprises acetylating delipidated bacterial residues of bacteria cells and isolating the watersoluble extracts by physico-chemical means. Said extracts are useful as immunological adjuvants in veterinary and human therapy.

Acetylated watersoluble extracts of corynebacteria, process for

Watersoluble extracts of corynebacteria cells are obtained by a process which comprises the steps of subjecting bacterial residues of corynebacteria containing diaminopimelic acid, e.g. Corynebacterium parvum cells, to a mild extraction and of isolating the watersoluble extracts so obtained by physico-chemical methods. Said extracts are useful as immunological adjuvants.

Watersoluble extracts of corynebacteria, process for obtaining them and

Hydrosoluble extracts of mycobacteria suitable as immunological adjuvants are prepared. These extracts have a molecular weight between 3,500 and 30,000 and adjuvant, non-arthrogenic properties. The delipidated bacterial residues of mycobacteria are subjected to a mild extraction, then the so-obtained substance is isolated and purified by physicochemical methods, or the delipidated bacterial residues of mycobacteria are treated by means of pyridine optionally in the presence of acetic anhydride, then the obtained products are treated with ethanol or water, and the hydrosoluble substances are isolated and purified by physicochemical methods.

Hydrosoluble extracts of mycobacteria

Hydrosoluble extracts of mycobacteria suitable as immunological adjuvants are prepared. These extracts have a molecular weight between 3,500 and 30,000 and adjuvant, non-arthrogen properties. The delipidated bacterial residues of mycobacteria are subjected to a mild extraction, then the so-obtained substance is isolated and purified by physicochemical methods, or the delipidated bacterial residues of mycobacteria are treated by means of pyridine, optionally in the presence of acetic anhydride, then the obtained products are treated with ethanol or water, and the hydrosoluble substances are isolated and purified by physicochemical methods.

Growing community of inventors

Paris, France

Pierre Jolles